Company / Financials
NOVAVAX INC Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$1.1B
FY2025 · +64.7% YoY
Net Income
$440.3M
FY2025 · +334.8% YoY
Profit Margin
39.2%
FY2025 · net income / revenue
ROE
-
FY2025 · return on equity
Total Assets
$1.2B
FY2025
Total Debt
-
FY2025
Equity
-$127.8M
FY2025
ROA
37.4%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -0.87 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.5%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$1.1B+64.7% YoYNet Income HistoryProfit after all expenses and taxes$440.3M+334.8% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$73.0M-64.0% YoYOperating Income HistoryProfit from core business operations before interest and taxes$452.8M+281.9% YoYSG&A Expense HistorySelling, general, and administrative expenses$157.5M-53.3% YoYR&D Expense HistoryResearch and development spending$342.3M-12.5% YoYInterest Expense HistoryCost of borrowing and debt obligations$11.5M+10.5% YoYIncome Tax HistoryTotal income tax expense$1.9M-82.9% YoYEPS (Basic) HistoryBasic earnings per share-$5.41+35.7% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$5.41+35.7% YoY